StockNews.AI
LBRX
StockNews.AI
1 min

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

1. LB Pharmaceuticals granted equity award to new SVP James Rawls. 2. Mr. Rawls receives options to purchase 90,000 shares at $14.61 each. 3. Positive Phase 2 trial data for LB-102 supports its advancement. 4. LB-102 may enter Phase 3 trials for schizophrenia and bipolar depression. 5. Potential to address various neuropsychiatric disorders with LB-102.

5m saved
Insight
Article

FAQ

Why Bullish?

The positive trial data and leadership changes could enhance market confidence. Historical examples show pipeline advancements can significantly boost stock prices.

How important is it?

The insights on LB-102's clinical progress and executive change are crucial to LBRX’s future.

Why Long Term?

Successful Phase 3 trials can lead to drug approval and sustained revenue. Previous drug approvals in biotech typically show a long-term positive market response.

Related Companies

AMRSNVCRALNY
November 12, 2025 16:15 ET  | Source: LB Pharmaceuticals Inc NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to James Rawls, the new Senior Vice President of Regulatory Affairs of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on November 10, 2025, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Rawls entering into employment with LB Pharmaceuticals. Mr. Rawls received an option to purchase 90,000 shares of LB Pharmaceuticals’ common stock. The option carries a ten-year term and an exercise price per share equal to $14.61, which was the closing price of LB Pharmaceuticals’ common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continuous service through the applicable vesting dates. About LB-102 LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia. About LB Pharmaceuticals LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. ContactsMedia: Michael TattoryLifeSci Communications Mtattory@lifescicomms.comInvestor Relations: Joyce Allaire LifeSci Advisors JAllaire@LifeSciAdvisors.com

Related News